Immune Repertoire Sequencing Market Size

Immune Repertoire Sequencing Market size was over USD 1.14 Billion in 2023 and is projected to exceed USD 2.65 Billion by the end of 2036, witnessing over 6.7% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of immune repertoire sequencing is evaluated at USD 1.25 Billion. The market is primarily driven by the escalating government encouragement for pharmacogenomics-based drug recovery. Furthermore, growth in multiple therapeutic areas such as cardiology, pain management, oncology, infectious diseases, and others is estimated to boost the market expansion in the projected period.

Additionally, the industry has been driven by many organizations seeking answers to biomarkers of the immune system. Mergers and acquisitions are also driving the market. More collaboration, acquisition, and agreement among the market players are majorly contributing to the industry growth. In order to produce effective and creative immunotherapies ArcherDX and Ambry Genetics joined hands in March 2018.